SouthBreeze: The type of analysis Jason has done on LymPro in the past, where he has done it based on assumptions rather than specific "quantitative guidance" was appropriate for a diagnostic still 6 to 12 months out from "launch." But Lympro is now a few weeks away from launch. For Gerald to not give any more than "we'll get a significant portion of the 150 million" is not good enough. "Significant portion" could mean 100 million or 10 million. No way Jason can do any meaningful analysis based on the vagary of that guidance.

We're close enough to "launch" that Gerald should tighten up his revenue guidance.